Tumor necrosis factor-alpha, interleukin 1, and phorbol myristate acetate are independent activators of NF-kappa B which differentially activate T cells.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Tumor necrosis factor-alpha, interleukin 1, and phorbol myristate acetate are independent activators of NF-kappa B which differentially activate T cells.

Cytokine. 1991 Sep;3(5):372-9. Unique Identifier : AIDSLINE MED/92089516
Krasnow SW; Zhang LQ; Leung KY; Osborn L; Kunkel S; Nabel GJ; Howard Hughes Medical Institute, University of Michigan Medical; Center, Department of Internal Medicine, Ann Arbor 48109-0650.

Abstract: Gene expression in eukaryotic cells can be altered in different ways by extracellular agents, including mitogens and cytokines. Such differential gene expression is mediated in part through the effects of these stimuli on distinct sets of cellular transcription factors. In this report, the effects of phorbol myristate acetate, tumor necrosis factor-alpha (TNF-alpha), and interleukin 1 (IL-1) on differential gene expression in the LBRM mouse T-lymphoma cell line are examined. Although these three different stimuli produce similar levels of induction of the NF-kappa B transcription factor, it is reported that they cause differential expression of other cellular activation genes, including c-fos and IL-2. The roles of IL-1 and TNF-alpha were also analyzed in EL-4 cells in the presence of a second activator, ionomycin. IL-1, but not TNF-alpha, was found to stimulate the IL-2 enhancer in the presence of this costimulator. These findings suggest that one transcription factor can be the target of cellular activators that exert otherwise different effects on gene expression. Cellular activation pathways can therefore be defined by the set of transcription factors stimulated within a cell. This approach may allow a more precise definition of the requirements for differential gene activation in different cell types and thereby provide a basis for the selective manipulation of gene expression in cytokine-responsive cells.

Keywords: Animal Base Sequence DNA Enhancer Elements (Genetics) Gene Expression Regulation HIV/GENETICS Interleukin-1/*PHARMACOLOGY Interleukin-2/SECRETION *Lymphocyte Transformation Lymphoma, T-Cell Mice Molecular Sequence Data NF-kappa B/DRUG EFFECTS/*METABOLISM Proto-Oncogene Proteins c-jun/METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes/*IMMUNOLOGY Tetradecanoylphorbol Acetate/*PHARMACOLOGY Tumor Cells, Cultured Tumor Necrosis Factor/*PHARMACOLOGY JOURNAL ARTICLE
920430
M9240902

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .